WO2025078984 - SUBSTITUTED TRICYCLIC COMPOUNDS AS KRAS DEGRADERS
National phase entry is expected:
Publication Number
WO/2025/078984
Publication Date
17.04.2025
International Application No.
PCT/IB2024/059901
International Filing Date
10.10.2024
Title **
[English]
SUBSTITUTED TRICYCLIC COMPOUNDS AS KRAS DEGRADERS
[French]
COMPOSÉS TRICYCLIQUES SUBSTITUÉS UTILISÉS EN TANT QU'AGENTS DE DÉGRADATION DE KRAS
Applicants **
AURIGENE ONCOLOGY LIMITED
39-40(P), KIADB Industrial Area, Electronics City Phase II, Karnataka
Bangalore 560100, IN
Inventors
CHIKKANNA, Dinesh
#103, First Main, Second cross, Nisarga Layout, Bannerghatta-Jigani Main Road
Bangalore 560083, IN
AELURI, Madhu
G-20, Balaji Serenity, Hilalige Road, Glass Factory Layout, Electronic City Phase II
Karnataka
Bangalore 560100, IN
MUKHERJEE, Subhendu
B208, SLV Sankalpa, Naganathapura, Central Jail Road
Bangalore 560100, IN
TATYASAHEB GORE, Suraj
Nandur Bk. Taluka: Rahata, District: Ahmednagar, State: Maharashtra
Ahmednagar 413720, IN
ABBINENI, Chandrasekhar
Plot#387, IKIGAI, Journalists' colony phase 3, Gopanpally
Hyderabad 500032, IN
MAKKIKOPPA VITTALARAO, Ravindra
#151, Makkikoppa
Kulur Post, Koppa Taluk
Chickmagaluru District
Chickmagaluru 577123, IN
BASAK, Debajyoti
Professor Colony, Lane no -5, Kenduadihi, Bankura, West Bengal
Kenduadihi 722102, IN
SAMAJDAR, Susanta
R801, HMTambourine, JP Nagar 6thPhase
Bangalore 560078, IN
SIMONOVICH, Scott
1801 Harbor Bay Parkway
Alameda, California 94502, US
GREEN, Evan
1701 Harbor Bay Parkway
Alameda, California 94502, US
MURRAY, Jeremy
1701 Harbor Bay Parkway
Alameda, California 94502, US
MISHRA, Nigam
1701 Harbor Bay Parkway
Alameda, California 94502, US
CHEN, Jun
1701 Harbor Bay Parkway
Alameda, California 94502, US
RAIKAR, Sandeep
1701 Harbor Bay Parkway
Alameda, California 94502, US
SHERER, Brian
250 King of Prussia Rd.
Radnor, Pennsylvania 19087, US
NGUYEN, Huy
1701 Harbor Bay Parkway
Alameda, California 94502, US
FERREIRA, Andrew
1701 Harbor Bay Parkway
Alameda, California 94502, US
MAUNG, Jack
1701 Harbor Bay Parkway
Alameda, California, US
COLE, David
1701 Harbor Bay Parkway
Alameda, California 94502, US
KHRAKOVSKY, Dimitri
1701 Harbor Bay Parkway
Alameda, California 94502, US
BUI, Minna
1701 Harbor Bay Parkway
Alameda, California 94502, US
Priority Data
202341067839
10.10.2023
IN
202441054021
15.07.2024
IN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| Sequence Listing | * |
| International Search Report is established | *
International Searching Authority
EPO
* |
| Applicant's Legal Status |
Legal Entity
* * * * * |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 5822 | |
| EPO | Filing, Examination | 39900 | |
| Japan | Filing | 560 | |
| South Korea | Filing | 611 | |
| USA | Filing, Examination | 18335 |
Total: 65228 USD
Abstract[English]
The present invention provides substituted tricyclic compound of formula (I), which are therapeutically useful as KRAS degraders. These compounds are useful in the treatment and/or prevention of diseases or disorders dependent upon KRAS. The present invention also provides pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt or a stereoisomer or a tautomer thereof thereof.[French]
La présente invention concerne des composés tricycliques substitués de formule (I), ayant une utilité thérapeutique en tant qu'agents de dégradation de KRAS. Ces composés sont utiles dans le traitement et/ou la prévention de maladies ou de troubles dépendant de KRAS. La présente invention concerne également des compositions pharmaceutiques comprenant un composé de formule (I) ou un sel pharmaceutiquement acceptable ou un stéréoisomère ou un tautomère de celui-ci.